Search results

Articles (5)

Journals (0)

1-5 of 5 results for Biosimilar SB2

Sort by:

Relevance

Select all

Sort by:

Relevance

Open accessResearch articleFirst published 2023

PERFUSE: a French non-interventional study of patients with inflammatory bowel disease receiving infliximab biosimilar SB2: a 12-month analysis

Yoram Bouhnik, Bruno Fautrel, Laurent Beaugerie [...]

Therapeutic Advances in Gastroenterology

Open accessResearch articleFirst published 2021

Long-term effectiveness,safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab

Sarah Fischer, Sarah Cohnen, Entcho Klenske [...]

Therapeutic Advances in Gastroenterology

Open accessResearch articleFirst published 2021

Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study

Davide Massimi, Brigida Barberio, Lorenzo Bertani [...]

Therapeutic Advances in Gastroenterology

Open accessResearch articleFirst published 2024

Reverse switching from the biosimilar SB2 to the originator infliximab in previously switched patients with inflammatory bowel diseases: results of a prospective long-term cohort study

Sarah Fischer, Moritz Donhauser, Sarah Cohnen [...]

Therapeutic Advances in Gastroenterology

Open accessReview articleFirst published 2019

Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective

Ágnes Milassin, Anna Fábián, Tamás Molnár

Therapeutic Advances in Gastroenterology

Search results

Articles (5)

Journals (0)

1-5 of 5 results for Biosimilar SB2

Sort by:

Relevance

Select all

Sort by:

Relevance

Open accessResearch articleFirst published 2023

PERFUSE: a French non-interventional study of patients with inflammatory bowel disease receiving infliximab biosimilar SB2: a 12-month analysis

Yoram Bouhnik, Bruno Fautrel, Laurent Beaugerie [...]

Therapeutic Advances in Gastroenterology

Open accessResearch articleFirst published 2021

Long-term effectiveness,safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab

Sarah Fischer, Sarah Cohnen, Entcho Klenske [...]

Therapeutic Advances in Gastroenterology

Open accessResearch articleFirst published 2021

Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study

Davide Massimi, Brigida Barberio, Lorenzo Bertani [...]

Therapeutic Advances in Gastroenterology

Open accessResearch articleFirst published 2024

Reverse switching from the biosimilar SB2 to the originator infliximab in previously switched patients with inflammatory bowel diseases: results of a prospective long-term cohort study

Sarah Fischer, Moritz Donhauser, Sarah Cohnen [...]

Therapeutic Advances in Gastroenterology

Open accessReview articleFirst published 2019

Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective

Ágnes Milassin, Anna Fábián, Tamás Molnár

Therapeutic Advances in Gastroenterology